Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results

Wilson Robert, Anzueto Antonio, Miravitlles Marc, Arvis Pierre, Alder Jeff, Haverstock Daniel, Trajanovic Mila, Sethi Sanjay

Source: Eur Respir J 2012; 40: 17-27
Journal Issue: July
Disease area: Airway diseases, Respiratory infections

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Wilson Robert, Anzueto Antonio, Miravitlles Marc, Arvis Pierre, Alder Jeff, Haverstock Daniel, Trajanovic Mila, Sethi Sanjay. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J 2012; 40: 17-27

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy of azithromycin vs. ciprofloxacin in the treatment of patients with acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2002; 20: Suppl. 38, 544s
Year: 2002

Short and long-term outcomes of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): The MOSAIC study
Source: Eur Respir J 2003; 22: Suppl. 45, 566s
Year: 2003

Antibiotic treatment and prevention of exacerbations of COPD
Source: Eur Respir Monogr 2013; 60: 96-106
Year: 2013


Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval
Source: Eur Respir J 2004; 24: 947-953
Year: 2004



Placebo-controlled, double-blind trial of chronic, intermittent ‘pulse‘ therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data
Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients
Year: 2006


Short-term efficacy of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): A multivariate analysis from the MOSAIC study
Source: Eur Respir J 2003; 22: Suppl. 45, 351s
Year: 2003

Health status following an acute exacerbation of chronic bronchitis (AECB) is better in patients receiving gemifloxacin compared with clarithromycin
Source: Eur Respir J 2001; 18: Suppl. 33, 542s
Year: 2001

Efficacy and safety of moxifloxacin in the outpatient treatment of exacerbations of chronic obstructive pulmonary disease
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018


Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors
Source: Annual Congress 2003 - Acute exacerbations of asthma and COPD
Year: 2003


Antibiotic treatment and prophylaxis
Source: Annual Congress 2006 - Infections and chronic obstructive lung diseases
Year: 2006


5-day moxifloxacin versus 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis: a cost-minimization analysis
Source: Eur Respir J 2003; 22: Suppl. 45, 336s
Year: 2003

Late-breaking abstract: Moxifloxacin (MXF) vs amoxicillin/clavulanic acid (AMC) in acute exacerbations of COPD (AECOPD): Results of a large clinical trial with a novel endpoint
Source: Annual Congress 2011 - Mechanisms and outcomes of infective exacerbations of COPD
Year: 2011


Why short-term antibiotic use in AECB may influence long-term outcomes
Source: Annual Congress 2005 - Antibiotic therapy: short- and long-term outcomes in LRTI
Year: 2005

Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in PROTEKT years 1–5 (1999–2004)
Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients
Year: 2006


Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD
Source: Eur Respir J 2009; 34: 1066-1071
Year: 2009



Clinical evaluation of patients with acute exacerbation of chronic bronchitis treated emperically with telithromycin
Source: Eur Respir J 2004; 24: Suppl. 48, 638s
Year: 2004

Greatest International ANti-infective Trial (GIANT) – the German cohort: moxifloxacin treatment provides short- and long-term benefits in AECB patients
Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients
Year: 2006


Comparison of the efficacy of azythromycin and roxithromycin in the treatment of acute purulent exacerbation of chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: Suppl. 33, 138s
Year: 2001

Efficacy of moxifloxacin for treatment of bronchial colonisation in COPD patients: a randomised, double-blind, placebo-controlled study
Source: Annual Congress 2007 - Treatment and care of COPD
Year: 2007



Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis: the  BEST-2 trial
Source: International Congress 2018 – Bronchiectasis: new insights in diagnosis and treatment
Year: 2018